|
TMEM164 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
5.71009906025211E-11 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
7.735200E-03 |
| Stage1-vs-Stage3 |
1.911790E-01 |
| Stage1-vs-Stage4 |
9.98420002229494E-09 |
| Stage2-vs-Stage3 |
7.387300E-04 |
| Stage2-vs-Stage4 |
2.47959999977176E-07 |
| Stage3-vs-Stage4 |
1.723860E-03 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
1.62592161956354E-12 |
| Normal-vs-Asian |
1.62447832963153E-12 |
| Caucasian-vs-AfricanAmerican |
8.473000E-01 |
| Caucasian-vs-Asian |
1.572400E-01 |
| AfricanAmerican-vs-Asian |
5.161800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
8.587400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
1.40759999989193E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.638800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.797800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.894400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.549600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.298400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.976000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.62219999999947E-07 |
| Classical-VS-Follicular |
3.08599999998549E-07 |
| Classical-VS-Other |
6.104600E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
1.71751501909512E-12 |
| Tall-VS-Other |
1.912590E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
3.234600E-01 |
| Follicular-VS-Normal |
1.8330892359586E-12 |
| Other-VS-Normal |
2.97439999996651E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
1.08150044475508E-10 |
|
|
